166 related articles for article (PubMed ID: 35371428)
1. A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study.
Mead AJ; Butt NM; Nagi W; Whiteway A; Kirkpatrick S; Rinaldi C; Roughley C; Ackroyd S; Ewing J; Neelakantan P; Garg M; Tucker D; Murphy J; Patel H; Bains R; Chiu G; Hickey J; Harrison C; Somervaille TCP
Ther Adv Hematol; 2022; 13():20406207221084487. PubMed ID: 35371428
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients With Myelofibrosis: A Case Series.
Gerds A; Su D; Martynova A; Pannell B; Mukherjee S; O'Neill C; Sekeres M; O'Connell C
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e463-e468. PubMed ID: 30115545
[TBL] [Abstract][Full Text] [Related]
4. Ruxolitinib for myelofibrosis in elderly non-transplant patients: healthcare resource utilization and costs.
Gerds AT; Yu J; Shah A; Xi A; Kumar S; Scherber R; Parasuraman S
J Med Econ; 2023; 26(1):843-849. PubMed ID: 37294103
[TBL] [Abstract][Full Text] [Related]
5. A case-based discussion of clinical problems in the management of patients treated with ruxolitinib for myelofibrosis.
Ho PJ; Bajel A; Burbury K; Dunlop L; Durrant S; Forsyth C; Perkins AC; Ross DM
Intern Med J; 2017 Mar; 47(3):262-268. PubMed ID: 28260257
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy and safety of ruxolitinib in the management of myelofibrosis: A single institution experience in Taiwan.
Chen YY; Huang CE; Lee KD; Chen CC
Hematology; 2016 Jan; 21(1):3-9. PubMed ID: 26214121
[TBL] [Abstract][Full Text] [Related]
7. Early intervention in myelofibrosis and impact on outcomes: A pooled analysis of the COMFORT-I and COMFORT-II studies.
Verstovsek S; Kiladjian JJ; Vannucchi AM; Mesa RA; Squier P; Hamer-Maansson JE; Harrison C
Cancer; 2023 Jun; 129(11):1681-1690. PubMed ID: 36840971
[TBL] [Abstract][Full Text] [Related]
8. Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial.
Mead AJ; Milojkovic D; Knapper S; Garg M; Chacko J; Farquharson M; Yin J; Ali S; Clark RE; Andrews C; Dawson MK; Harrison C
Br J Haematol; 2015 Jul; 170(1):29-39. PubMed ID: 25824940
[TBL] [Abstract][Full Text] [Related]
9. Real-World Assessment of Clinical Outcomes in Patients with Lower-Risk Myelofibrosis Receiving Treatment with Ruxolitinib.
Davis KL; Côté I; Kaye JA; Mendelson E; Gao H; Perez Ronco J
Adv Hematol; 2015; 2015():848473. PubMed ID: 26635878
[TBL] [Abstract][Full Text] [Related]
10. Ruxolitinib for myelofibrosis--an update of its clinical effects.
Kantarjian HM; Silver RT; Komrokji RS; Mesa RA; Tacke R; Harrison CN
Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):638-45. PubMed ID: 24238036
[TBL] [Abstract][Full Text] [Related]
11. Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis.
Verstovsek S
Postgrad Med; 2013 Jan; 125(1):128-35. PubMed ID: 23391678
[TBL] [Abstract][Full Text] [Related]
12. Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes.
Gerds AT; Yu J; Scherber RM; Paranagama D; Kish JK; Visaria J; Singhal M; Verstovsek S; Pemmaraju N
Acta Haematol; 2022; 145(4):448-453. PubMed ID: 35008087
[TBL] [Abstract][Full Text] [Related]
13. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.
Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Tiu RV; Zachee P; Jourdan E; Winton E; Silver RT; Schouten HC; Passamonti F; Zweegman S; Talpaz M; Lager J; Shun Z; Mesa RA
Lancet Haematol; 2017 Jul; 4(7):e317-e324. PubMed ID: 28602585
[TBL] [Abstract][Full Text] [Related]
14. Recommendations on the use of ruxolitinib for the treatment of myelofibrosis.
Devos T; Selleslag D; Zachée P; Benghiat FS
Hematology; 2018 May; 23(4):194-200. PubMed ID: 29022420
[TBL] [Abstract][Full Text] [Related]
15. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
Harrison C; Kiladjian JJ; Al-Ali HK; Gisslinger H; Waltzman R; Stalbovskaya V; McQuitty M; Hunter DS; Levy R; Knoops L; Cervantes F; Vannucchi AM; Barbui T; Barosi G
N Engl J Med; 2012 Mar; 366(9):787-98. PubMed ID: 22375970
[TBL] [Abstract][Full Text] [Related]
16. Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy.
Pemmaraju N; Bose P; Rampal R; Gerds AT; Fleischman A; Verstovsek S
Leuk Lymphoma; 2023 Jun; 64(6):1063-1081. PubMed ID: 37081809
[TBL] [Abstract][Full Text] [Related]
17. Real-World Outcomes of Ruxolitinib in Patients With Myelofibrosis Focusing on Red Blood Cell Transfusion: A Multicenter Study From the MPN Working Party of the Korean Society of Hematology.
Jung EH; Hong J; Kim SY; Park Y; Yuh YJ; Mun YC; Lee WS; Park SK; Bang SM
Clin Lymphoma Myeloma Leuk; 2022 Oct; 22(10):e931-e937. PubMed ID: 35858905
[TBL] [Abstract][Full Text] [Related]
18. Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial.
Koschmieder S; Isfort S; Schulte C; Jacobasch L; Geer T; Reiser M; Koenigsmann M; Heinrich B; Wehmeyer J; von der Heyde E; Tesch H; Gröschl B; Bachhuber P; Großer S; Pahl HL
Ann Hematol; 2023 Dec; 102(12):3383-3399. PubMed ID: 37792065
[TBL] [Abstract][Full Text] [Related]
19. Optimizing the management of patients with myelofibrosis.
Manea PJ
Clin J Oncol Nurs; 2014 Jun; 18(3):330-7. PubMed ID: 24867113
[TBL] [Abstract][Full Text] [Related]
20. State-of-the-Art Review on Myelofibrosis Therapies.
Wang F; Qiu T; Wang H; Yang Q
Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):e350-e362. PubMed ID: 34903489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
